Piper Sandler analyst David Westenberg raised the firm’s price target on Neogen to $17 from $14 and keeps a Neutral rating on the shares. Westenberg said he updated the firm’s model to reflect the company’s updated guidance of $1B in revenue and $300M in EBITDA by FY25. The analyst said that although he lowered some estimates, he increased his price target based on increased comp multiples.
Published first on TheFly
